Novo Nordisk's Weight Loss Pill 'Wegovy' Approved by FDA

FDA Approval for Oral Weight Loss Medication

• FDA has approved Novo Nordisk's weight-loss pill, which contains semaglutide, the same active ingredient found in injectable medications like Wegovy and Ozempic.
• The pill will be marketed under the brand name Wegovy and is available in a 25 mg dosage.

Clinical Study and Patient Population

• A 64-week late-stage study demonstrated that participants taking 25 mg of oral semaglutide daily experienced greater average body weight loss compared to those on a placebo.
• The approval is for chronic weight management in adults who are obese or overweight and have at least one weight-related health condition.

Market Impact and Novo Nordisk's Position

• This approval targets a significant market, potentially reaching tens of millions of patients, in a global market projected to be worth $150 billion annually by the next decade.
• The new pill could help Novo Nordisk recover from a challenging year marked by declining share prices and profit warnings, especially as its injectable Wegovy faces increased competition.
• Shares of Novo Nordisk rose 8%, while competitor Eli Lilly's shares fell 1% following the announcement.

Future Outlook for Oral Semaglutide

• Novo Nordisk's executive vice president of US operations believes a daily pill could significantly increase interest and adoption of the drug.
• Analysts predict that oral semaglutide could capture approximately one-fifth of the market by 2030.